Pharming Group (NASDAQ:PHAR) Shares Gap Down – What’s Next?

Pharming Group (NASDAQ:PHAR)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $8.09, but opened at $7.79. Pharming Group shares last traded at $7.85, with a volume of 677 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have commented on PHAR shares. Oppenheimer upped their target price on shares of Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a research report on Friday, March 14th. HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 20th.

Pharming Group Stock Down 0.5 %

The firm has a market cap of $547.65 million, a price-to-earnings ratio of -30.96 and a beta of -0.08. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The firm’s fifty day moving average is $8.57 and its two-hundred day moving average is $8.70.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The company had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. On average, sell-side analysts expect that Pharming Group will post -0.2 EPS for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.